

## ASX Announcement

### Recce Pharmaceuticals to Present at Investor Conference

**SYDNEY, Australia, 30 May 2018:** Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing a new class of synthetic antibiotics, today announced Executive Director James Graham will attend and present in front of up to 200 investors at the forthcoming Finance News Network investor conference in Sydney on Tuesday 5 June between 12:30pm and 2:30pm.

The opportunity includes a pre-recorded interview for public viewing, highlighting the growing global interest in the Company's new class of antibiotics, and will be available on the corporate websites of Shaw and Partners, ANZ, St. George Bank, Westpac, Thomas Reuters, and Sequoia Finance Group.

The investor presentation will be released to the ASX and available on the Company's website.

The event is free but attendees are advised to [register](#) to ensure a seat.

#### About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a [new class of synthetic antibiotics with broad spectrum activity](#) designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE<sup>®</sup> 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results. Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-man clinical trials.



ASX: RCE

**Head Office** Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (0)2 8075 4585 **F** +61 (0)2 8075 4584  
**R&D Centre - Perth** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899  
**Washington Office** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA